A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17
Sutro Biopharma Price Target Maintained With a $11.00/Share by Piper Sandler
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $11 to $17
Sutro Biopharma (STRO) Gets a Buy From Wedbush
Truist Financial Issues a Buy Rating on Sutro Biopharma (STRO)
Sutro Biopharma Analyst Ratings
Sutro Biopharma's Promising ADC Innovations and Strategic Collaborations Justify a Buy Rating
Piper Sandler Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $11
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $12 to $17
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $5 to $17
Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Buy Rating for Sutro Biopharma Backed by Promising Luvelta Phase 1b Trial Results
Sutro Biopharma Analyst Ratings
Sutro Biopharma's Promising Oncology Prospects and Solid Financials Merit a Buy Rating
JMP Securities Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $17
Sutro Biopharma Analyst Ratings
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Cuts Target Price to $15
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17
Sutro Biopharma's Strong Financials and Clinical Progress Reinforce Buy Rating
No Data
No Data